Zacks Investment Research cut shares of Solid Biosciences (NASDAQ:SLDB) from a buy rating to a hold rating in a research report released on Saturday morning, Zacks.com reports.

According to Zacks, “Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001, a gene transfer candidate which is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients’ muscles. Solid Biosciences LLC is headquartered in Cambridge, Massachusetts. “

A number of other research firms have also issued reports on SLDB. Leerink Swann upgraded shares of Solid Biosciences from a market perform rating to an outperform rating in a research note on Monday, August 19th. Credit Suisse Group dropped their price objective on shares of Solid Biosciences from $6.00 to $2.00 and set a hold rating on the stock in a research note on Tuesday, November 12th. Chardan Capital upgraded shares of Solid Biosciences from a neutral rating to a buy rating and lifted their price objective for the company from $7.50 to $10.00 in a research note on Friday, August 16th. ValuEngine upgraded shares of Solid Biosciences from a hold rating to a buy rating in a research note on Thursday, August 1st. Finally, Citigroup lowered shares of Solid Biosciences from a neutral rating to a sell rating and set a $6.00 price target for the company. in a research note on Thursday, August 29th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the stock. The company presently has an average rating of Hold and an average price target of $8.56.

Shares of SLDB traded up $0.20 during mid-day trading on Friday, reaching $3.69. 46,657 shares of the stock traded hands, compared to its average volume of 1,245,711. The firm has a market cap of $161.42 million, a price-to-earnings ratio of -1.66 and a beta of 1.90. The stock has a fifty day simple moving average of $9.98 and a 200 day simple moving average of $7.73. Solid Biosciences has a 12-month low of $2.75 and a 12-month high of $34.34. The company has a quick ratio of 6.78, a current ratio of 6.78 and a debt-to-equity ratio of 0.05.

Several large investors have recently modified their holdings of the stock. Matisse Capital increased its stake in shares of Solid Biosciences by 4.4% in the third quarter. Matisse Capital now owns 68,900 shares of the company’s stock worth $712,000 after buying an additional 2,900 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Solid Biosciences by 20.7% in the third quarter. Rhumbline Advisers now owns 23,842 shares of the company’s stock worth $247,000 after buying an additional 4,094 shares during the last quarter. Atria Investments LLC bought a new stake in shares of Solid Biosciences in the second quarter worth $472,000. Walleye Trading Advisors LLC bought a new stake in shares of Solid Biosciences in the second quarter worth $210,000. Finally, Walleye Trading LLC bought a new stake in shares of Solid Biosciences in the second quarter worth $214,000. Institutional investors and hedge funds own 46.11% of the company’s stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.

Further Reading: What is a Real Estate Investment Trust (REIT)?

Get a free copy of the Zacks research report on Solid Biosciences (SLDB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Solid Biosciences (NASDAQ:SLDB)

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.